GlaxoSmithKline Consumer Healthcare Q2 '05 PAT up 45.5%, Gurgaon, July 22, 2005
22 July 2005
GlaxoSmithKline Consumer Healthcare Q2 '05 PAT up 45.5%
Gurgaon, July 22, 2005
The increase in PAT is driven by continuing strong sales performance, favourable input prices and a wide-ranging cost reduction programme.
"We are very focused on innovation. It is great to see consumers react so positively to our pipeline of new products," said Nick Massey, Managing Director, GlaxoSmithKline Consumer Healthcare Ltd. "Overall input costs have shown some improvement over last year. I'm also encouraged by our internal cost containment, in particular the many excellent initiatives to control overheads."
PBT for the quarter ended June 30, 2005, amounted to Rs. 44 crore (against Rs.29.6 crores in Q2 2004). PAT stood at Rs.29.1 crore, against Rs.18.6 crores in Q2 2004. For the six months ended June 30, 2005, PBT stood at Rs.81.6 Crore and PAT at Rs.55.5 Crore, 36.7% and 45.5% over 2004 levels.
About GlaxoSmithKline Consumer Healthcare Ltd.
GSKCH, which was established in 1958, is an associate of GlaxoSmithKline plc. of the U.K, a global science based healthcare company. GSKCH has continually benefited from the technical and marketing inputs that have been available as a consequence of this association. GSKCH is one of the largest players in the health food drinks industry. The Company with its manufacturing plants located in Nabha, Rajahmundry and Sonepat has a total workforce of about 2700 people.
GSKCH has a strong marketing and distribution network in India comprising over 1800 wholesalers and direct coverage of over 4,50,000 retail outlets. Its flagship product, Horlicks, is a widely regarded and highly respected brand for over 100 years. The Company also manufactures and markets Boost, Viva and Maltova and in addition markets and distributes a number of products in diverse categories, which include prominent household names such as Eno, Crocin and Iodex.